R&D | December 01, 2025
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
